Novel coronavirus pneumonia (NCP) (coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has evolved into a global pandemic. Patients with COVID-19 typically present respiratory symptoms. However, extrapulmonary presentations are common. Digestive symptoms such as diarrhea, abdominal pain and jaundice are frequently reported in patients with COVID-19. Furthermore, COVID-19 patients could present digestive symptoms only and no respiratory presentations. Evidence has reported that the severity of these respiratory and digestive symptoms, when they show, are closely associated.
The intestinal damage caused by SARS-CoV-2 infection has been verified by autopsy and biopsy. The SARS-COV-2 RNA has been detected in the feces of COVID-19 patients. Angiotensin-converting enzyme 2 (ACE2) is the functional receptor of SARS-CoV, and is critical to the cellular entry of SARS-CoV. It is reported that ACE2 expression is roughly 100-fold higher in the gastrointestinal tract (particularly the colon) than in the respiratory system.
The digestive tract may serve as an infection route for COVID-19 according to clinical and pathological evidence. We should pay more attention to the digestive symptoms reported in patients infected with the virus, and consider SARS-CoV-2 stool test to help diagnosis and monitor for viral clearance.
This Research Topic aims to explore the clinical characters of COVID-19 patients with digestive symptoms, and to unveil the pathogenic mechanisms of SARS-CoV-2 in the digestive system, holding potential for the improvement of prevention, diagnosis, and treatment for the concerned patients.
We welcome submissions of Original Research and Review covering the following subtopics:
? COVID-19 and the gastro-intestinal tract, liver and the pancreas
? Fecal SARS-COV-2 transmission and detection
? ACE2 and SARS-COV-2 interaction in the digestive system
? Diagnosis, treatment and prevention of SARS-COV-2 infection in the digestive system
? SARS-COV-2 infection in patients with underlying inflammatory bowel disease
? SARS-COV-2 infection in patients with underlying chronic liver disease
? SARS=COV-2 infection and gastrointestinal endoscopy
? Safety and protection of gastroenterology and endoscopy personnel for COVID-19
Novel coronavirus pneumonia (NCP) (coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has evolved into a global pandemic. Patients with COVID-19 typically present respiratory symptoms. However, extrapulmonary presentations are common. Digestive symptoms such as diarrhea, abdominal pain and jaundice are frequently reported in patients with COVID-19. Furthermore, COVID-19 patients could present digestive symptoms only and no respiratory presentations. Evidence has reported that the severity of these respiratory and digestive symptoms, when they show, are closely associated.
The intestinal damage caused by SARS-CoV-2 infection has been verified by autopsy and biopsy. The SARS-COV-2 RNA has been detected in the feces of COVID-19 patients. Angiotensin-converting enzyme 2 (ACE2) is the functional receptor of SARS-CoV, and is critical to the cellular entry of SARS-CoV. It is reported that ACE2 expression is roughly 100-fold higher in the gastrointestinal tract (particularly the colon) than in the respiratory system.
The digestive tract may serve as an infection route for COVID-19 according to clinical and pathological evidence. We should pay more attention to the digestive symptoms reported in patients infected with the virus, and consider SARS-CoV-2 stool test to help diagnosis and monitor for viral clearance.
This Research Topic aims to explore the clinical characters of COVID-19 patients with digestive symptoms, and to unveil the pathogenic mechanisms of SARS-CoV-2 in the digestive system, holding potential for the improvement of prevention, diagnosis, and treatment for the concerned patients.
We welcome submissions of Original Research and Review covering the following subtopics:
? COVID-19 and the gastro-intestinal tract, liver and the pancreas
? Fecal SARS-COV-2 transmission and detection
? ACE2 and SARS-COV-2 interaction in the digestive system
? Diagnosis, treatment and prevention of SARS-COV-2 infection in the digestive system
? SARS-COV-2 infection in patients with underlying inflammatory bowel disease
? SARS-COV-2 infection in patients with underlying chronic liver disease
? SARS=COV-2 infection and gastrointestinal endoscopy
? Safety and protection of gastroenterology and endoscopy personnel for COVID-19
